Pregnancy is one of the most significant periods of physiological change in a woman’s life, and the choices made during this period — about diet, physical activity, medication, and substance use — have consequences not only for the mother but for the developing foetus. For women who smoke and become pregnant, the imperative to stop smoking is one of the most clearly evidence-based recommendations in obstetric medicine: smoking during pregnancy is associated with increased risk of miscarriage, preterm birth, low birth weight, placental abruption, and sudden infant death syndrome, among numerous other adverse outcomes.
For women who vape when they become pregnant, the clinical picture is more complicated. The advice of Irish healthcare providers — broadly consistent with UK guidance from NICE — is that vaping is substantially less harmful than smoking and that a pregnant woman who cannot or does not stop smoking should be supported to switch to vaping as a harm reduction measure. But vaping is not without risk in pregnancy, and this guide provides an honest account of what is and is not known about those risks.
Why Smoking in Pregnancy Is So Harmful
Understanding why smoking in pregnancy causes harm is important context for assessing vaping in pregnancy, because it reveals which components of cigarette smoking are responsible for which outcomes. Cigarette smoke exposes the foetus to a complex mixture of several thousand compounds, many of which are demonstrably toxic to developing tissue. The best-understood among these are carbon monoxide, nicotine, and the broader category of combustion products including polycyclic aromatic hydrocarbons and nitrosamines.
Carbon monoxide binds to haemoglobin in both maternal and foetal blood with greater affinity than oxygen, reducing the oxygen-carrying capacity of the blood and creating a state of chronic hypoxia in the developing foetus. This oxygen deprivation impairs foetal growth, brain development, and organ maturation, and is one of the primary mechanisms behind the low birth weight and preterm birth outcomes associated with smoking in pregnancy.
Nicotine crosses the placenta and accumulates in foetal tissue, where its effects on the developing nervous system are of particular concern. Nicotinic acetylcholine receptors are expressed early in foetal development and play important roles in the organisation of the developing brain and peripheral nervous system. Chronic nicotine exposure during critical developmental windows disrupts this signalling in ways that are associated with long-term effects on cognitive function, impulse control, and respiratory regulation in the offspring.
The combustion-specific compounds — which are entirely absent from vaping aerosol — contribute to placental damage, chromosomal damage in foetal cells, and the inflammatory states associated with preterm labour. Their absence from vaping is the primary reason that vaping is considered substantially less harmful in pregnancy than smoking, when the comparison is between a smoking pregnant woman and a vaping one.
The Evidence on Vaping in Pregnancy
The evidence on vaping in pregnancy is substantially less developed than the evidence on smoking, for the practical reason that pregnant women have not been enrolled in randomised controlled trials of vaping. The ethical constraints on experimental research with pregnant participants mean that the available evidence comes from observational studies, animal models, and mechanistic research rather than the controlled trial evidence that would provide the highest level of certainty.
The most significant trial relevant to this area is the MPOWER trial, conducted in the UK and published in 2020, which examined switching from cigarettes to e-cigarettes during pregnancy. While not primarily focused on birth outcomes, the trial found that the majority of participants who switched to e-cigarettes were able to sustain the switch through pregnancy, and that birth weight outcomes were broadly comparable to those in the group who reduced smoking rather than switching completely. The trial was not powered to detect differences in rarer adverse outcomes.
Observational data comparing outcomes in pregnant women who smoke versus those who vape consistently finds better outcomes in the vaping group on the measures most strongly driven by carbon monoxide and combustion products — birth weight, gestational age at delivery, and placental function indicators. This finding is consistent with the expectation that removing combustion-specific compounds would improve these outcomes, even if nicotine exposure is maintained.
Nicotine’s Specific Risks in Pregnancy
The most important caveat in the harm reduction case for vaping in pregnancy is that nicotine itself — regardless of delivery mechanism — carries specific risks to foetal development that are not resolved by switching from smoking to vaping. Nicotine crosses the placenta efficiently, accumulates in foetal tissue, and acts on the developing foetal nervous system during the same critical periods that make smoking so harmful to neurodevelopment.
Animal studies using nicotine alone — without any combustion products — have demonstrated effects on foetal lung development, brain organisation, and autonomic nervous system maturation. These findings are consistent with the understanding that nicotine is a pharmacologically active compound with specific developmental effects that are not dependent on how it is delivered. A foetus exposed to nicotine from a patch, from a vaping device, or from a cigarette is exposed to the same compound and, at equivalent blood levels, experiences the same receptor-level effects.
This does not mean that all nicotine delivery mechanisms are equivalent in pregnancy — they are not, because the combustion-specific components of cigarette smoke add substantially to the harm profile. But it does mean that the goal in pregnancy should be to minimise total nicotine exposure where possible, rather than simply switching delivery mechanism and maintaining the same nicotine intake.
Practical Guidance for Pregnant Women Who Vape
The current guidance from NICE in England, which Irish clinical practice generally follows in this area, is that pregnant women who smoke should be encouraged and supported to switch to e-cigarettes if this helps them stop smoking, as the risks from continued smoking substantially exceed the risks from vaping. This is a pragmatic harm reduction position that reflects the reality that for some women, switching to vaping rather than quitting all nicotine use is achievable where quitting entirely is not.
For pregnant women who are already vaping and did not smoke cigarettes, the guidance is more cautious. There is no established harm reduction benefit from vaping for a pregnant woman who was not a smoker — the comparison is not with cigarettes but with no nicotine use, which is always the safest option in pregnancy. Women who were vaping before pregnancy and want to continue are making a different risk calculation than women who are switching from cigarettes.
Practically, pregnant women who vape should discuss their vaping with their midwife or obstetrician honestly and early in pregnancy. Healthcare providers in Ireland are now generally informed about vaping and its risk profile relative to smoking, and a constructive conversation about reduction strategies — including stepping down nicotine concentration, reducing vaping frequency, and potentially transitioning to licensed NRT products — is available through the maternity care system. Carbon monoxide monitoring, available at many maternity services, specifically tests for combustion product exposure and can verify that a woman who has switched from cigarettes to vaping has eliminated that exposure.
The Irish HSE and Stopping Smoking in Pregnancy
The HSE operates a dedicated QUIT service for smoking cessation that includes specific support for pregnant women. This service offers free individual counselling, referral to group support, and access to licensed nicotine replacement therapy products at reduced cost for pregnant women. The QUIT service is staffed by trained cessation specialists who understand the harm reduction context and can provide evidence-based advice on switching from smoking to vaping as part of a cessation journey.
HSE guidance explicitly acknowledges that for pregnant women who cannot stop using nicotine products, vaping is preferable to continued smoking. This is a significant evolution from earlier guidance that treated all nicotine use in pregnancy as equally unacceptable. Pregnant women who feel their healthcare provider is not engaging with the harm reduction evidence on vaping can request a referral to the QUIT service or to a smoking cessation specialist within the maternity service.
The goal in pregnancy, from a public health perspective, is the outcome that maximises foetal health given the realistic constraints of the individual woman’s situation. For a woman who smokes heavily and cannot quit using any method, switching to vaping is a genuine improvement in foetal outcomes. For a woman who was vaping lightly before pregnancy, reducing nicotine exposure to the lowest manageable level during pregnancy is the appropriate harm reduction strategy. Individual clinical guidance, rather than blanket rules, serves pregnant women better in this area than any single recommendation can.